AveXis (NASDAQ:AVXS) had its target price increased by Barclays from $124.00 to $152.00 in a research note released on Friday morning. They currently have an overweight rating on the stock.

Several other equities research analysts have also weighed in on AVXS. Citigroup set a $132.00 price objective on AveXis and gave the company a buy rating in a research note on Friday, January 5th. Canaccord Genuity set a $110.00 price objective on AveXis and gave the company a hold rating in a research note on Wednesday, December 20th. BidaskClub lowered AveXis from a hold rating to a sell rating in a research note on Thursday, December 14th. Bank of America lowered their price objective on AveXis from $115.00 to $112.00 and set a buy rating on the stock in a research note on Friday, November 10th. Finally, Credit Suisse Group began coverage on AveXis in a research note on Wednesday, January 17th. They issued an outperform rating and a $134.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $115.37.

AveXis (NASDAQ AVXS) opened at $109.54 on Friday. AveXis has a 12 month low of $53.94 and a 12 month high of $128.00.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60. Following the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $168,690.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total value of $188,960.00. Following the transaction, the vice president now directly owns 7,000 shares in the company, valued at approximately $661,360. The disclosure for this sale can be found here. Insiders sold a total of 57,560 shares of company stock worth $6,160,062 over the last three months. 18.60% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of AVXS. Janus Henderson Group PLC acquired a new position in AveXis during the 2nd quarter worth $55,439,000. State Street Corp lifted its holdings in AveXis by 104.2% during the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after buying an additional 510,189 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in AveXis during the 3rd quarter worth $39,563,000. Perceptive Advisors LLC lifted its holdings in AveXis by 147.5% during the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after buying an additional 400,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in AveXis by 31.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock worth $129,419,000 after buying an additional 380,396 shares in the last quarter. 81.52% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “AveXis (AVXS) Price Target Raised to $152.00” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://theolympiareport.com/2018/02/12/avexis-avxs-price-target-raised-to-152-00.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.